Rutgers has been instrumental in getting the coronavirus vaccines to the public – most recently leading one of the largest phase 3 clinical trials sites in the world for the FDA emergency-use authorized Johnson & Johnson vaccine, which is expected to play a pivotal role in stemming the pandemic. Behind the university’s crucial efforts at New Jersey Medical School and Robert Wood Johnson Medical School is a Rutgers-led collaborative established two years ago to create clinical trial innovations that can speed the translation of research discoveries into improved patient care. “Who could have imagined this would be needed so quickly?” said Barbara Tafuto, instructor in the health informatics department at the School of Health Professions and member of workforce development for the NJ Alliance for Clinical and Translational Science’s $29 million grant program known as NJACTS. To read the full story.